**Applications**

ANZGOG’s Fund for New Research Grant Program’s purpose is
to promote the development of future clinical trials to
achieve ANZGOG’s vision of ‘*Advancing research, saving lives*.’

Donors have significantly contributed to the 2023 Program with a focus on:

* Survivorship
* Uterine cancer – one project minimum to be awarded
* Ovarian cancer – one project minimum to be awarded
* Cervical, vaginal or vulval cancer

**Maximum for individual grants will be $50,000**

* ANZGOG members only
(Early Career Researchers are encouraged to apply)
* A maximum of **one** application by each member (including 1 for co-investigators) may be submitted.
* No institutional overhead will be supported.

**Research Projects and Priority**

Priority will be given to projects which complete the form correctly and describe how the project will lead to a larger study or clinical trial. [Clinical, translational, pre-clinical and survivorship projects will be assessed separately.]

*Clinical projects may include:*

* Pilot or feasibility studies (if intended to generate data to support preparation for a larger research project).
* Sub-studies of clinical studies already underway, such as clinical studies, QOL etc.
* Projects that have commenced recruitment **are not eligible**.
* Projects proposing a clinical trial in Australia and/or New Zealand led by international counterparts **are not eligible.**

 *Translational projects may include:*

* New translational sub-studies of current or prior trials.

*Pre-clinical projects may include:*

* Drug therapies for molecular subtypes.
* Research that will contribute to clinical trial design or refinement.

 **Note:** Pre-clinical and translational concepts will be assessed on potential clinical application, considering the likelihood of findings either leading to a clinical trial, assisting in the design, or supporting the translational component of a clinical trial.

Submissions must:

* Have direct alignment with ANZGOG’s research goals clearly feasible and achievable within the budget and timeframe proposed.
* Be fully funded either by this ANZGOG grant or in combination with other funding. Proof of other funding is required before contracting. NB: If other funding is required and not secured within 3 months of ANZGOG’s offer, the Fund for New Research Grant offer may be withdrawn.

**Timeline 2023**

|  |  |
| --- | --- |
| 18 September 2023 | Applications close |
| 05 October 2023 | RAC Meeting – approval to proceed to funding review |
| November 2023 | Grant Panel review  |
| 23 November 2023 | Board of Directors meeting |
| 30 November 2022 | Final applicant notifications  |
| January 2024 | Contracting with successful applicants |

**Funding and grant review**

The ANZGOG Board of Directors makes the final decision on funds available, and the amount per project, and approves the confidential grant panel’s recommendation.

**Recognition for ANZGOG**

Each project will receive an ANZGOG project number and will be recognised on all publications with the words “Research and funding collaboration with ANZGOG.”

Please ensure that **all** fields on the form are completed, including a lay summary.
***If any requested information is missing, the form will be deemed incomplete and will not be considered for a grant.***

NAME OF APPLICANT / PRINCIPAL INVESTIGATOR

|  |  |
| --- | --- |
| Name: | Organisation: |
| Speciality: | Email: |
| Phone: | Mobile: |

Please attach a copy of the Applicant / Principal Investigator’s CV (3 pages maximum).

Please ensure you complete the list of ALL investigators and relevant publications on the last page of this application.

Please do not attach additional information/appendices not requested as this will not be considered.

|  |  |
| --- | --- |
| Research Title |  |
| Which category of research does your application belong to? | 🞎 Clinical 🞎 Translational sub-study 🞎 Pre-clinical |
| Study Phase | 🞎 Pilot 🞎Phase I 🞎 Phase II 🞎 Phase III 🞎 Other ……………… |
| Speciality | 🞎 Medical 🞎 Surgical 🞎 Radiation oncology 🞎 Quality of life/Symptom benefit 🞎 Rare tumour research🞎 Other …………………………………………………………………………… |
| Cancer Type | 🞎 Cervical 🞎 Uterine 🞎 Ovarian 🞎 Other - specify |
| Research Aim |  |
| Project Duration | 🞏 Short term <12 months 🞏 Medium term 2-3 years  🞏 Long Term 5+ years |
| *Describe how the project will lead to a larger study or clinical trial [must be included]* |  |
| How will your project contribute to improving the outcomes and quality of life for women with gynaecological cancer? [100 words] |   |
| *Lay summary for consumer research adviser and public communications[must be included]*[250 words] |  |
| What other organisations will collaborate on this project? | [Universities, Hospitals, clinical trials groups, Quality of Life Office, Health Economics groups] List or attach [one page maximum]  |
| Background and Significance [750 words maximum] |  |
| Hypothesis |  |
| Objectives |  |
| Endpoints |  |
| Subject Population |  |
| Clinical Trial Protocol | 🞎 In development:  🞎 Yes, if a study chair has been appointed who is this?Name & Institution: 🞎 No Assistance required from ANZGOG to develop further: 🞎 Yes 🞎 No 🞎N/A Comment if applicable \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Study Procedures / Experimental design[750 words maximum] |  |
| Statistical Considerations |  |
| Feasibility |  |
| Biospecimen Collection /Translational Research (TR)  | For clinical trial concepts: TR sub-study overview (if applicable) |
| If biospecimens to be utilised:🞎 Existing archival collection  If existing, is the use compliant with patient consent? 🞎 Yes 🞎 No 🞎 Prospective collection🞎 To be determined |
| Quality of Life Assessment \* |  |
| Health Economics\* |  |
| Drugs and sponsorship | Drug: Pharma Co:Will pharma provide drug? Yes 🞎 No 🞎 N/A 🞎Pharma contact information: |

\* Questions are not applicable to applications that are not clinical trials, e.g. preclinical studies

**FUNDING**

|  |  |
| --- | --- |
| Total Funds Requested from ANZGOG*(Maximum $100,000)* | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Please provide budget details below |
| Have you applied for, or are you receiving, funding from other organisations for this project? | 🞎 No 🞎 Yes, please specifyFunderAmount |

 **Detailed Budget - example**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Budget excluding GST | Year 1 | Year 2 | Year 3 | Total |
| Staff (list) |  |  |  |  |
| Operational costs |  |  |  |  |
| Consumables |  |  |  |  |
| Other |  |  |  |  |
| Note: Attach your budget separately if preferred. |

**INVESTIGATOR/S**

Names of ALL Investigators should be supplied in the surname-last format with the initial in capital. Institutional affiliations should be indicated with superscript numbers following the author’s name.

All affiliations should contain institution, city and country.

Example:
J Smith1, S Doe1
1 Department of Oncology, XYZ Hospital, Sydney, Australia

|  |
| --- |
| **Investigator/s (list all)** |
|  **Affiliations (list all the institutions)** |
| Track record of Principal Investigator and other key participants | List key points (Principal Investigator’s CV to be attached separately – 3 pages maximum) |
| List of relevant publications | List or attach (one page maximum) |

***CHECKLIST FOR APPLICATION INCLUSIONS*:**

**🞏 A.** Application Form – Fund for New Research grant

**🞏 B.** Principal Investigator’s CV

**APPENDIX 1** - Guidelines for completing your concept

 **RESEARCH TITLE**

* For trials, this should be in the PICO format (i.e. the title should hold information on the participants, Intervention and Comparison groups, and the Outcomes of the trial).

**BACKGROUND AND SIGNIFICANCE**

* Have you addressed the scientific validity?
* Is it an important question?
* Size of population defined?
* Sufficient rationale to proceed?
* Is it clinically relevant?
* Have you searched ANZCTR and other registries? [www.anzctr.org.au](http://www.anzctr.org.au)

**STUDY SUMMARY**

* Aims: Are they clearly stated?
* Trial objectives: Do they match aims?
* Hypotheses: Are they clearly stated?

Do they match aims and objectives?

* Endpoints: Are they measurable?

Are they suitable to answer
trial questions?

**STUDY DESIGN AND STATISTICS**

* Phase of study?
* Is design appropriate to address
the question?
* Are treatment arms clearly described?
* What is the sample size estimate?
* Is the sample size justified in terms of primary endpoint?
* Is the study likely to detect a clinically significant difference? NB: Preclinical concepts should identify and explain the likely process from obtaining preclinical outcomes to the development of a clinical trial, if applicable.
* Has a statistician reviewed the
study design?
* Is the study feasible? Outline the proposed sources of subjects and estimated recruitment rates.

**SUBJECT POPULATION**

* Target population and setting should be described briefly. Main inclusion criteria – are they clearly stated and clinically relevant?

**STUDY INTERVENTION**

* Briefly describe actions to be taken

**FUNDING**

* Is there any financial support for the study?

**TRANSLATIONAL RESEARCH**

* For clinical studies, is there a translational research component? Briefly describe any rationale, pilot data and methods, including anticipated biospecimen collection, if known.
* For pre-clinical studies, is there proposed clinician and industry involvement to support clinical trial development? Has toxicity and dosage been considered?
* TR-ANZGOG Network Laboratory support is available to assist with collection, processing and storing biospecimens for ANZGOG trials, and provision of specialised media as required, subject to capacity.

**OTHER**

* Have QOL and Health Economics assessments been included?
* Is there collaborative support from other trials groups